The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As2O3) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these drugs inhibit cell growth and induce apoptosis in several cell lines, but few data are reported on leukemic blasts. The aim of this study was to evaluate the biological effects on non-M3 Acute Myeloid Leukemia (AML) cells. Blasts of six patients, after exposition to Atra and As2O3 were tested for growth inhibition, induction of apoptosis and change in cell cycle distribution, evaluating cell viability, percentage of apoptotic cells and of blasts positive for Ki-67 and BrdU. In the present study we demonstrated that either Atra or As2O3 inhibit leukemic cells proliferation by induction of apoptosis. The effects are time and dose dependent. We did not observe additive or synergistic effects with the combination of the drugs. Further, our results showed that Atra and As2O3 have effects on cell cycle distribution reducing S-phase and proliferating cells. These results should be taken in to account preparing future laboratory and clinical experimental protocols that associate these drugs with antineoplastic agents with different cell cycle specificity.
|Data di pubblicazione:||2005|
|Titolo:||Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts|
|Autore/i:||M. Cosenza; M. Civallero; S. Sacchi; R. Marcheselli; S. Pozzi|
|Codice identificativo ISI:||WOS:000225877800014|
|Codice identificativo Scopus:||2-s2.0-13244289904|
|Citazione:||Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts / M. Cosenza; M. Civallero; S. Sacchi; R. Marcheselli; S. Pozzi. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 46(2)(2005), pp. 257-263.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris